SOURCE: Derma Sciences, Inc.

July 11, 2006 10:05 ET

Taglich Brothers Initiates Coverage on Derma Sciences, Inc.

NEW YORK, NY -- (MARKET WIRE) -- July 11, 2006 -- Taglich Brothers, Inc. announces it initiated coverage of Derma Sciences, Inc. (OTC BB: DSCI).

Derma Sciences, Inc. based in Princeton, New Jersey, manufactures wound care dressings, wound closure fasteners and skin care products for sale to healthcare institutions, physicians' offices, home healthcare agencies and pharmacies, mainly in the US and Canada. The company also operates as a contract manufacturer of wound care products for major healthcare supply distributors. Its production facilities are in Canada and China

The complete 22-page report is available at

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

* The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the above-mentioned report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. In April 2006, Taglich Brothers underwrote an offering of 7,548,064 Derma Sciences' common shares at $0.60 per share and 1,887,016 warrants exercisable at $1.00 per share. Taglich Brothers employees acquired 754,806 warrants, distributed as follows: Michael Taglich (194,312), Robert Taglich (194,312), Vincent Palmieri (100,000), Michael Brunone (52,000), Douglas Hailey (44,182), Richard Oh (30,000), Robert Schroeder (20,000) and Russell Bernier (20,000). The remaining 100,000 warrants will be distributed among investment banking staff prior to the end of 2006. As of the date of this report, the following officers of the firm owned or controlled restricted common shares and additional warrants acquired through their participation in the April 2006 private placement of Derma Sciences common shares: Michael Taglich (416,966 shares; 145,700 warrants) and Robert Taglich (416,664 shares; 104,166 warrants). All research issued by Taglich Brothers, Inc. is based on public information. The company paid a monetary engagement fee of $21,000 (USD) for the first year of creation and dissemination of research reports and will pay a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for these services after the first year.

Contact Information

  • Contact:
    Richard Oh
    Taglich Brothers